Introduction {#s1}
============

TNFα-induced protein 3 interacting with protein 1(*TNIP1*), located on chromosome 5q32-q33.1, encodes the A20 binding inhibitor of the NF-κB1 (ABIN1) protein. *TNIP1* is an important regulator of NF-κB activity, playing an important role in maintaining homeostasis of the immune system [@pone.0095573-Wagner1]. Recently, genome-wide association and replication analysis studies have shown that genes in the NF-κB pathway such as TNFα-induced protein 3 (*TNFAIP3*) and *TNIP1* are associated with several autoimmune diseases including systemic lupus erythematosus (SLE) [@pone.0095573-Gateva1]--[@pone.0095573-Zhong1], psoriasis [@pone.0095573-Nair1]--[@pone.0095573-Sun1], psoriatic arthritis (PsA) [@pone.0095573-Bowes1], systemic sclerosis (SSc), and rheumatoid arthritis (RA) [@pone.0095573-Allanore1]--[@pone.0095573-Zhang1].

Vogt-Koyanagi-Harada (VKH) syndrome and Behçet's disease (BD),manifesting as bilateral panuveitis,are two of the most common uveitis entities encountered in China [@pone.0095573-Yang1]. Numerous studies have indicated that intrinsic factors play an important role in the development of these diseases. BD and VKH syndrome present a familial aggregation and a geographic distribution. BD is particularly common in populations of the Far East and the Mediterranean basin along the ancient silk route and VKH syndrome is mostly observed in Asians, Amerindians and Hispanics [@pone.0095573-Sakane1]. Human leukocyte antigen (HLA) class genes have been shown to be strongly associated with BD and VKH syndrome in populations with different ethnic backgrounds. HLA-DRB1,HLA-DR4/ DRw53 and HLA-DR1 are connected with the susceptibility to VKH syndrome in Japanese (90% of VKH patients have them) and the same results were found in Chinese, Indian, Korean, Mexican, and Hispanic patients [@pone.0095573-Damico1]--[@pone.0095573-Kim1]. HLA-B51/B5 is the most prominent immunogenetic susceptibility factor for BD in multiple ethnic groups [@pone.0095573-deMenthon1].

However, HLA genes only account for part of the genetic-risk effect for VKH syndrome or Behcet's disease, highlighting the fact that much of the heritable basis for these diseases remains unknown and implicating a possible role for non-HLA genes. Increasing evidence indicates that autoimmune diseases such as SLE, RA and Crohn's disease share common risk genes with Behcet's disease and VKH, including genes such as interleukin-23 receptor(*IL23R*) [@pone.0095573-Jiang1]--[@pone.0095573-Mizuki1], protein tyrosine phosphatase non-receptor type 22 (*PTPN22*) [@pone.0095573-Horie1]--[@pone.0095573-Baranathan1] and signal transducer and activator of transcription 4 (*STAT4*) [@pone.0095573-Yi1]--[@pone.0095573-Shen1].

The aim of the present study was to investigate the association of *TNIP1* gene variants with the risk for BD and VKH syndrome, which to our knowledge, has not yet been reported.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

A total of 656 BD patients, 961VKH syndrome patients and 1534 healthy controls were included in this two-stage study. All patients were recruited from the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) or the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) and fulfilled the VKH syndrome and BD disease international criteria respectively [@pone.0095573-Read1]--[@pone.0095573-Mignogna1]. All patients and controls belong to the Chinese Han population and were matched according to age and geographic area.

In this two-stage study, 377 BD, 374 VKH syndrome patients and 480 healthy controls were used to find out the susceptible SNPs (Pc\<0.05) in the first stage study. In the second stage study, we added another 279 BD and/or 587 VKH syndrome patients and 1054 controls to replicate the associated SNPs indentified in the first stage study. Clinical findings of BD and VKH syndrome patients are presented in [Table 1](#pone-0095573-t001){ref-type="table"} and [Table 2](#pone-0095573-t002){ref-type="table"}. This study was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. Written informed consent was obtained from all the subjects after explaining the purpose of the study. All procedures were carried out in compliance with the principles of the Declaration of Helsinki.

10.1371/journal.pone.0095573.t001

###### Clinical features of BD patients used for the first and second stage study.

![](pone.0095573.t001){#pone-0095573-t001-1}

  Clinical features          BD patients in the first stage Total(377)    \%    BD patients in the second stage Total(279)    \%
  ------------------------- ------------------------------------------- ------ -------------------------------------------- ------
  Age at onset (years±SD)                    33.6±9.0                                            33.7±8.3                   
  Male                                          217                      57.6                      218                       78.1
  Female                                        160                      42.4                       61                       21.9
  Uveitis                                       377                      100                       279                       100
  Oral ulcer                                    355                      94.2                      266                       95.3
  Gentle ulcer                                  219                      58.1                      160                       57.3
  Hypopyon                                      95                       25.2                       75                       26.9
  Skin lisions                                  269                      71.3                      212                       76.0
  Positive pathergy test                        104                      27.6                       32                       11.5
  Arthritis                                     57                       15.1                       25                       9.0

10.1371/journal.pone.0095573.t002

###### Clinical features of VKH syndrome patients used for the first and second stage study.

![](pone.0095573.t002){#pone-0095573-t002-2}

  Clinical features          VKH patients in the first stage Total(374)    \%    VKH patients in the second stage Total(587)    \%
  ------------------------- -------------------------------------------- ------ --------------------------------------------- ------
  Age at onset (years±SD)                    37.7±13.3                                            40.8±14.2                   
  Male                                          206                       55.1                       312                       53.2
  Female                                        168                       44.9                       275                       46.9
  Neck stiffness                                 34                       9.1                        71                        12.1
  Alopecia                                      139                       37.2                       246                       41.9
  Poliosis                                      124                       33.2                       233                       39.7
  Vitiligo                                       63                       16.9                       114                       19.4
  Dysacusia                                      82                       21.9                       217                       37.0
  Tinnitus                                      149                       39.8                       282                       48.0
  Scalp hypersensitivity                         55                       14.7                       90                        15.3

SNP selection {#s2b}
-------------

SNP selection was based on published data. Seven SNPs of *TNIP1*, including rs17728338, rs7708392, rs10036748, rs3762999, rs999556, rs4958881 and rs3792783, were selected. These 7 SNPs have been proven to be associated with autoimmune diseases including SLE, psoriasis, psoriatic arthritis (PsA) and systemic sclerosis(SSc) [@pone.0095573-Gateva1]--[@pone.0095573-Zhang1]. The frequencies of these seven SNPs are higher than 0.10 in Chinese Han according to the dbSNP (<http://www.ncbi.nlm.nih.gov/SNP/>).

Genotyping {#s2c}
----------

Peripheral blood samples were collected in ethylenediamine tetraacetic acid (EDTA) anti-coagulated tubes and kept at −80°C until used. Genomic DNA was extracted by the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The target *TNIP1* gene sequences were amplified by polymerase chain reaction (PCR) and the 7 SNPs were subsequently genotyped and analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis using primers,enzymes and conditions as shown in [Table 3](#pone-0095573-t003){ref-type="table"}. The primers were designed using Primer Premier 5.0 software (Premier Biosoft International, Palo Alto, CA).

10.1371/journal.pone.0095573.t003

###### Primer sequences and restriction enzymes used for RFLP analysis of the *TNIP1* gene.

![](pone.0095573.t003){#pone-0095573-t003-3}

  SNP             Forward primer sequence     Reverse primer sequence   Tm(°C)   Enzyme
  ------------ ----------------------------- ------------------------- -------- ---------
  rs17728338    TTCAGAACAGTGGCTACTCTCCTCCTC    CATTCGGGAGCCTTTTGCCA       66      NCOI
  rs7708392        TTTCCCAATGCTGCTAAGGA        TGGAACCTGGGTCTCTTCTG       60     Hpy188I
  rs10036748    CACGTATGAGAAAAATAAAATAGTCA    GATCAAGTCTCAGCTCAAATGT      56     Hsp92II
  rs3762999      TAGGCAAGTTTTGGTCCTCAGCATC    GGCAATCCGCCTTTATTCATCCT     66      BSEGI
  rs999556         AGGCTTCCTATCCACCACCTA       AGACACTGCTCCTTCCTCTCC      60      BCNI
  rs4958881       GCTATAAGAAGCCCTTGAACCA      GTTCCCTCTTGGTGGTGTATGT      60      Hin1I
  rs3792783        CCAGAGAGTTGCCACAGGAAG       CTGTGTAGGTGCTCAAGGACG      61      XcmI

Each PCR reaction was performed in 6 µl containing 3 µl Premix Taq (Promega, Madison, USA), 2 pmoles primers and 0.1 µg of genomic DNA. The PCR conditions were as follow: initial denaturation at 95°C for 5 minutes followed by 36 cycles of denaturation at 94°C for 30 seconds, annealing at 56--58°C (56°C for rs17728338, rs7708392, rs10036748 and rs3762999, 58°C for rs999556, rs4958881 and rs3792783) for 30 seconds, extension at 72°C for 30 seconds, and a final extension at 72°C for 5 minutes. PCR products were digested respectively with 2 U restriction enzymes ([Table 3](#pone-0095573-t003){ref-type="table"}) in 8 µl reaction volume overnight. Digestion products were visualized on a 4%--5% agarose gel and stained with GoldView (SBS Genetech, Beijing, China).

Randomly selected subjects (10% of all samples) were directly sequenced (Biomed, Beijing, China) to double check the validation of the PCR-RFLP results.

Statistical analysis {#s2d}
--------------------

Data analysis was performed using an SPSS statistical package (version 17.0, SPSS Inc., Chicago, IL, USA). Genotype frequencies were calculated by direct counting. Chi-square analysis was used to test for deviation of genotype frequencies from Hardy--Weinberg equilibrium. The frequency of alleles and genotypes between patients and controls were compared using χ^2^ test or Fisher's exact test and the probability of an association was corrected with the Bonferroni method. *P* Bonferroni correction values of \<0.05 were considered significant. Odds ratios (ORs) and 95% confidence intervals (95% CI) were also assessed.

Results {#s3}
=======

Genotype frequencies of tested seven SNPs in this study did not deviate from Hardy-Weinberg equilibrium in the case and control group (*P*\>0.05). In the first stage study, 377 BD, 374 VKH syndrome patients and 480 healthy controls were randomly chosen from the whole patient and healthy control cohort to find out the susceptible SNPs (*Pc*\<0.05). The results showed that the frequencies of the GG genotype and G allele of rs17728338 were significantly increased in VKH patients (Bonferroni *Pc* = 0.019, OR = 2.265, 95% CI  = 1.400-3.363; *Pc* = 0.014, OR = 2.170, 95% CI = 1.357-3.471; respectively). No significant difference was noted in allele or genotype frequencies of rs7708392, rs10036748, rs3762999, rs999556, rs4958881 and rs3792783, between VKH patients and healthy controls (Pc\>0.05). No significant difference was noted in allele or genotype frequencies of all tested 7 SNPs between BD patients and healthy controls. ([Table 4](#pone-0095573-t004){ref-type="table"})

10.1371/journal.pone.0095573.t004

###### Frequencies of alleles and genotypes of *TNIP1* polymorphisms in BD, VKH patients and controls in the first stage study.
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  SNPs          Genotype/allele   VKH(n = 374)   BD (n  = 377)   Controls (n  = 480)   P^a^ / Pc^a^        OR(95%CI)        P^b^ /Pc^b^        OR(95%CI)
  ------------ ----------------- -------------- --------------- --------------------- -------------- --------------------- ------------- ---------------------
  rs17728338          GG           349(93.3)       342(90.7)          413(86.0)        0.001/0.019    2.265(1.400--3.363)    0.036/ NS    1.585(1.028--2.445)
                      AG            25(6.7)         35(9.3)           67(14.0)                                                           
                       G           723(96.7)       719(95.4)          893(93.0)        0.001/0.014    2.170(1.357--3.471)    0.115/ NS    2.170(1.357--3.471)
                       A            25(3.3)         35(4.6)            67(7.0)                                                           
  rs7708392           CC           186 (49.7)      177(46.9)          244(50.8)         0.750/ NS     0.957(0.730--1.254)    0.259/ NS    0.856(0.653--1.121)
                      CG           152 (40.6)      168(44.6)          187(39.0)                                                          
                      GG            36(9.6)         32(8.5)           49(10.2)                                                           
                       C           524(70.1)       522(69.2)          675(70.3)         0.908/ NS     0.988(0.801--1.217)    0.628/ NS    0.950(0.772--1.169)
                       G           224(29.9)       232(30.8)          285(29.7)                                                          
  rs10036748          TT           221(59.1)       223(59.2)          277(57.7)         0.684/ NS     1.059(0.805--1.393)    0.987/ NS    0.998(0.746--1.334)
                      CT           138(36.9)       138(36.6)          183(38.1)                                                          
                      CC            15(4.0)         16(4.2)            20(4.2)                                                           
                       T           580(77.5)       584(77.5)          737(76.8)         0.707/ NS     1.405(0.832--1.312)    0.739/ NS    1.039(0.828--1.305)
                       C           168(22.5)       170(22.5)          223(23.2)                                                          
  rs3762999           AA           223(59.6)       218(57.8)          295(61.5)         0.586/ NS     0.926(0.702--1.221)    0.281/ NS    0.860(0.653--1.132)
                      AG           136(36.4)       142(37.7)          171(35.6)                                                          
                      GG            15(4.0)         17(4.5)            14(2.9)                                                           
                       A           582(77.8)       578(76.7)          761(79.3)         0.464/ NS     0.917(0.727--1.157)    0.194/ NS    0.859(0.682--1.081)
                       G           166(22.2)       176(23.3)          199(20.7)                                                          
  rs999556            AA            11(2.9)         13(3.4)            15(3.1)          0.877/ NS     0.939(0.426--2.070)    0.693/ NS    0.848(0.375--1.919)
                      AG           132(35.8)       142(37.7)          171(35.6)                                                          
                      GG           231(61.8)       222(58.9)          294(61.3)                                                          
                       A           154(20.6)       168(22.3)          201(20.9)         0.860/ NS     0.979(0.773--1.239)    0.502/ NS    1.083(0.859--1.365)
                       G           594(79.4)       586(77.7)          759(79.1)                                                          
  rs4958881           CT            40(10.6)        37(9.8)           71(14.8)          0.077/ NS     0.690(0.456--1.043)    0.029/ NS    0.627(0.411--0.957)
                      TT           334(89.4)       340(90.2)          409(85.2)                                                          
                       C            40(5.3)         37(4.9)            71(7.4)          0.088/ NS     0.707(0.474--1.055)    0.035/ NS    0.646(0.429--0.973)
                       T           708(94.7)       717(95.1)          889(93.6)                                                          
  rs3792783           CC            11(2.9)         12(3.2)            15(3.1)          0.877/ NS     0.939(0.426--2.070)    0.962/ NS    1.019(0.471--2.204)
                      CT           125(33.4)       120(31.8)          168(35.0)                                                          
                      TT           238(63.6)       245(65.0)          297(61.9)                                                          
                       C           147(19.7)       144(19.1)          198(20.6)         0.619/ NS     0.941(0.741--1.195)    0.432/ NS    0.908(0.715--1.154)
                       T           601(80.3)       610(80.9)          762(79.4)                                                          

CI, confidence intervals; OR, odds ratios; NS, not significant; *P*c value, the Bonferroni correction *P* values. *P*c^a^ value,the Bonferroni correction *P* values for VKH syndrome; *P*c^b^ value the Bonferroni correction *P* values for BD.

In the second stage study, we replicated the association of the rs17728338 polymorphism using another set of 587 VKH patients and 1054 controls. Genotypes distribution and allele frequencies are shown in [Table 5](#pone-0095573-t005){ref-type="table"}. The results showed a significantly increased frequency of the GG genotype and a decreased frequency of the AG genotype in VKH patients (*Pc* = 0.038; *Pc* = 0.038). The combined results also showed a significant association of SNP rs17728338 with VKH syndrome (*Pc* = 1.83×10^−4^, OR = 1.934, 95% CI  = 1.438--2.601).

10.1371/journal.pone.0095573.t005

###### Frequencies of alleles and genotypes of *TNIP1* polymorphisms in VKH patients and controls in the second stage and combined results.
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  Genotype/allele    VKH (n = 587)   Controls (n  = 1054)              *P*value(OR,95%CI)              *P*c value          *P* ^combined^ value(OR, 95%CI)           *P*c^combined^ value
  ----------------- --------------- ---------------------- ------------------------------------------ ------------ ------------------------------------------------ ----------------------
  GG                  548(93.3%)          935(88.9%)        0.002(OR = 1.788, 95% CI  = 1.227-2.606)     0.038      9.67×10^−6^(OR = 1.934 95% CI  = 1.438-2.601)        1.83×10^−4^
  AG                   39(6.7%)           119(11.1%)                                                                                                                
  G                   1135(96.7%)        1993(94.5%)        0.003(OR = 1.765, 95% CI  = 1.221-2.553)     0.042      1.74×10^−5^(OR = 1.871, 95% CI  = 1.400-2.500)       2.44×10^−4^
  A                    39(3.3%)           119(5.5%)                                                                                                                 

Subdivision of the patients according to the extraocular clinical findings, did not reveal an association of the tested seven SNPs with BD or VKH syndrome subgroups.

Discussion {#s4}
==========

In this study we show an association between a *TNIP1* rs17728338 gene polymorphism with VKH syndrome but not with BD. We found that the frequence of the AG genotype of rs17728338 was decreased in VKH patients, which suggests that it may play a protective role in the development of VKH syndrome in the Chinese Han population.

As a chronic multisystemic relapsing inflammatory disorder, VKH syndrome is characterized as a bilateral granulomatous panuveitis accompanied by meningitis, vitiligo, alopecia, poliosis, tinnitus and hearing loss [@pone.0095573-Bordaberry1]--[@pone.0095573-Fang1]. BD is characterized as a relapsing uveitis accompanied by recurrent oral aphthous ulcers, genital ulcerations with mucocutaneous, articular, neurologic, urogenital and vascular manifestations [@pone.0095573-Krause1]. Although clinical features of both diseases have been described comprehensively, their precise etiology and pathogenesis are still unclear. Other autoimmune diseases such as SLE, RA and psoriasis, which had been found with association with *TNIP1* polymorphisms, may share autoimmune features and mechanism with VKH syndrome and Behçet's disease (BD) [@pone.0095573-Yuan1].

*TNIP1* is a newly discovered gene influencing susceptibility to multiple immune-related diseases [@pone.0095573-Gateva1]--[@pone.0095573-Zhang1]. One of the important functions of *TNIP1* is to regulate NF-κB pathways. NF-κB pathways may promote the expression of genes and secretion of cytokines by human uveal melanocytes, which are considered antigen-presenting cells in human Vogt-Koyanagi-Harada disease [@pone.0095573-Hu1]. *TNIP1* can inhibit signaling pathways of various transmembrane receptors, such as the TNFα-receptor, epidermal growth factor receptor (EGF-R), toll-like receptors (TLR), nuclear receptors peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RARs) [@pone.0095573-Ramirez1]--[@pone.0095573-Gurevich2]. These receptors play key roles in regulating inflammation and inflammatory diseases.

A polymorphism of rs17728338 near *TNIP1* was first reported to be associated with psoriasis in Americans from European ancestry and subsequently confirmed in other Caucasian populations with PsA [@pone.0095573-Gateva1] [@pone.0095573-Sahin1]. In our study,we genotyped 7 SNPs of *TNIP1*. One of these SNPs, rs17728338, was observed to be associated with VKH syndrome, whereby the frequency of the A allele was shown to be decreased in VKH syndrome patients. Whether the observed rs17728338 polymorphism has implications concerning the biological function of *TNIP1* is not yet known as deserves further study. The other 6 SNPs were not associated with VKH although earlier studies showed that there was an association with autoimmune diseases such as SLE, RA and psoriasis. This suggests that the pathogenesis of VKH is different from these immune mediated diseases. This is not surprising since VKH is unique due to the fact that it is an autoimmune disease directed against melanocyte antigens.

We also investigated the relationship between the clinical features of VKH syndrome patients and *TNIP1* polymorphisms. These clinical features include neck stiffness, tinnitus, alopecia, poliosis, dysacusia, scalp hypersensitivity, and vitiligo. No significant association could be detected between *TNIP1* gene polymorphisms and the clinical features of VKH syndrome, but a larger sample size may be needed to resolve this issue.

There are limitations in our study. First, it is not clear whether the observed *TNIP1* rs17728338 polymorphism has implications concerning the biological function of *TNIP1*. Second, we did not observe an association with *TNIP1* gene polymorphisms with BD and it is possible that other relevant polymorphisms of this gene are associated with this uveitis entity. Furthermore the association of the *TNIP1* gene association with VKH syndrome was only performed in a Chinese Han population and further studies are needed in other ethnic populations.
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